Antisense oligonucleotides for inducing exon skipping and methods of use thereof
First Claim
Patent Images
1. An antisense oligonucleotide of 20 to 31 bases comprising a base sequence that is 100% complementary to consecutive bases of the human dystrophin pre-mRNA, wherein the base sequence comprises at least 20 consecutive bases of GGG AUC CAG UAU ACU UAC AGG CUC C (SEQ ID NO:
- 175), in which uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide induces exon 50 skipping;
or a pharmaceutically acceptable salt thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
250 Citations
2 Claims
-
1. An antisense oligonucleotide of 20 to 31 bases comprising a base sequence that is 100% complementary to consecutive bases of the human dystrophin pre-mRNA, wherein the base sequence comprises at least 20 consecutive bases of GGG AUC CAG UAU ACU UAC AGG CUC C (SEQ ID NO:
- 175), in which uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide induces exon 50 skipping;
or a pharmaceutically acceptable salt thereof.
- 175), in which uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide induces exon 50 skipping;
-
2. A pharmaceutical composition comprising:
- (i) an antisense oligonucleotide of 20 to 31 bases comprising a base sequence that is 100% complementary to consecutive bases of the human dystrophin pre-mRNA, wherein the base sequence comprises at least 20 consecutive bases of GGG AUC CAG UAU ACU UAC AGG CUC C (SEQ ID NO;
175), in which uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense oligonucleotide induces exon 50 skipping, or a pharmaceutically acceptable salt thereof; and
(ii) a pharmaceutically acceptable carrier.
- (i) an antisense oligonucleotide of 20 to 31 bases comprising a base sequence that is 100% complementary to consecutive bases of the human dystrophin pre-mRNA, wherein the base sequence comprises at least 20 consecutive bases of GGG AUC CAG UAU ACU UAC AGG CUC C (SEQ ID NO;
Specification